During a roughly five-year span, CVS Health, Cigna, and UnitedHealth benefited the most from increasing prices for generic drugs that treated illnesses such as HIV and cancer. Some of the price hikes ...

President-elect Donald Trump has not backed down from insisting that the United States needs to acquire Greenland, a Danish ...

President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland ...

Shares of Hershey Co. booked a double-digit percentage gain on Monday after Bloomberg reported that Oreo maker Mondelez International Inc. was exploring a possible acquisition of the iconic ...

The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound from Eli Lilly—has added fuel to an already fiery debate over the ...

These days, it feels like everyone is using Ozempic. The results have been astonishing: The average person taking Ozempic loses about 15 pounds after three months and 27 pounds after six months.

They called 2023 the year of Ozempic, but it now seems GLP-1 drugs might define an entire decade — or an even longer era. The game-changing drugs, which mimic the hormone GLP-1, offer large ...

Starting in the new year, Independence Blue Cross, the region’s largest health insurer, will no longer cover anti-obesity drugs like Ozempic and Wegovy when they’re prescribed solely for weight loss.

IF YOU TAKE a GLP-1 agonist like Ozempic or Zepbound, you can see changes to your waistline and your blood sugar within weeks. What might be less obvious is how the drug is affecting your brain.